Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-27 · 1381 Präparate · 72104 Quellenpassagen · 204 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)
Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4–5
HOS-222902 · Präparat HOS-217110
4
Medicinal product Medicinal products within Rationale
class class
Antianginal Ranolazine Increased plasma concentrations of
ranolazine which may increase the potential
for serious and/or life-threatening reactions
(see section 4.5).
Antiarrhythmics Amiodarone, Increased plasma concentrations of
dronedarone amiodarone and dronedarone. Thereby,
increasing the risk of arrhythmias or other
serious adverse reactions (see section 4.5).
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic
acid. The concomitant administration with
fusidic acid is contraindicated in
dermatological infections (see section 4.5).
Anticancer Neratinib Increased plasma concentrations of
neratinib which may increase the potential
for serious and/or life-threatening reactions
(see section 4.5).
Venetoclax Increased plasma concentrations of
venetoclax. Increased risk of tumor lysis
syndrome at the dose initiation and during
the ramp-up phase (see section 4.5).
Anti-gout Colchicine Increased plasma concentrations of
colchicine. Potential for serious and/or life-
threatening reactions in patients with renal
and/or hepatic impairment (see sections 4.4
and 4.5).
Antihistamines Astemizole, terfenadine Increased plasma concentrations of
astemizole and terfenadine. Thereby,
increasing the risk of serious arrhythmias
from these agents (see section 4.5).
Lurasidone Increased plasma concentrations of
lurasidone which may increase the potential
for serious and/or life threatening reactions
(see section 4.5)
Antipsychotics/ Pimozide Increased plasma concentrations of
Neuroleptics pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or
other serious adverse effects from this agent
(see section 4.5).
Quetiapine Increased plasma concentrations of
quetiapine which may lead to coma. The
concomitant administration with quetiapine
is contraindicated (see section 4.5).
Ergot alkaloids Dihydroergotamine, ergonovine, Increased plasma concentrations of ergot
ergotamine, methylergonovine derivatives leading to acute ergot toxicity,
including vasospasm and ischaemia (see
section 4.5).
GI motility agent Cisapride Increased plasma concentrations of
cisapride. Thereby, increasing the risk of
serious arrhythmias from this agent (see
section 4.5).
Hepatitis C virus direct Elbasvir/grazoprevir Increased risk of alanine transaminase
acting antivirals (ALT) elevations (see section 4.5).
Lipid-modifying agents
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) elbasvir (HOS-108814) methylergonovine (HOS-086155) dronedarone (HOS-086144) cisapride (HOS-085610) fusidic acid (HOS-086146) neratinib (HOS-086142) hepatitis C virus (HOS-108813) ergot alkaloids (HOS-108807) venetoclax (HOS-086143) lead (HOS-085592) grazoprevir (HOS-108815) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) ergotamine (HOS-086154) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) ergonovine (HOS-086153) dihydroergotamine (HOS-086152) alanine (HOS-088949)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-01T11:16:00Z · SHA-256 0fed296c6994925fa007baa09781245b754a9daf71b55237d53885c6a4bb3537 · Passage e29498532a1a198cec5cec7f0360275fb9d203cdb79cfcf40b326372e8bf2ff5 · Zeichen 1219–6293 im Abschnitt
Wechselwirkungen · Genvoya
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10
HOS-133938 · Präparat HOS-097520
9
Medicinal product by Effects on medicinal product Recommendation concerning
therapeutic areas levels. co-administration with Genvoya
Mean percent change in AUC,
Cmax, Cmin1
Anti-hepatitis C virus medicinal products
Ledipasvir (90 mg once daily)/ Ledipasvir: No dose adjustment of
Sofosbuvir (400 mg once daily)/ AUC: ↑ 79% ledipasvir/sofosbuvir and Genvoya
Elvitegravir (150 mg once daily)/ Cmin: ↑ 93% is warranted upon co-administration.
Cobicistat (150 mg once daily)/ Cmax: ↑ 65%
Emtricitabine (200 mg once daily)/
Tenofovir alafenamide (10 mg Sofosbuvir:
once daily)5 AUC: ↑ 47%
Cmin: N/A
Cmax: ↑ 28%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) ledipasvir (HOS-110493) hepatitis C virus (HOS-108813)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage f6708b7101bab9f5a39b99b4d18f06c592957e9df7db80f1c081aeb9f9d338d9 · Zeichen 10833–11772 im Abschnitt
Wechselwirkungen · Tenofovir disoproxil Viatris (previously Tenofovir disoproxil Mylan)
Tenofovir disoproxil Viatris 245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-223272 · Präparat HOS-217142
Increased systemic
exposure to didanosine
may increase didanosine
related adverse reactions.
Rarely, pancreatitis and
lactic acidosis,
sometimes fatal, have
been reported.
Co-administration of
tenofovir disoproxil and
didanosine at a dose of
400 mg daily has been
associated with a
significant decrease in
CD4 cell count, possibly
due to an intracellular
interaction increasing
phosphorylated (i.e.
active) didanosine. A
decreased dosage of
250 mg didanosine
co-administered with
tenofovir disoproxil
therapy has been
associated with reports of
high rates of virological
failure within several
tested combinations for
the treatment of HIV-1
infection.
Adefovir dipivoxil AUC: ↔ Tenofovir disoproxil
Cmax: ↔ should not be
administered
concurrently with
adefovir dipivoxil (see
section 4.4).
Entecavir AUC: ↔ No clinically significant
Cmax: ↔ pharmacokinetic
12
Medicinal product by Effects on drug levels Recommendation
therapeutic areas (dose in Mean percent change in AUC, Cmax, concerning
mg) Cmin co-administration with
245 mg tenofovir
disoproxil
interactions when
tenofovir disoproxil was
co-administered with
entecavir.
Hepatitis C virus antiviral agents
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma
(90 mg/400 mg q.d.) + AUC: ↑ 96% concentrations of
Atazanavir/Ritonavir Cmax: ↑ 68% tenofovir resulting from
(300 mg q.d./100 mg q.d.) + Cmin: ↑ 118% co-administration of
Emtricitabine/Tenofovir tenofovir disoproxil,
disoproxil Sofosbuvir: ledipasvir/sofosbuvir and
(200 mg/245 mg q.d.)1 AUC: ↔ atazanavir/ritonavir may
Cmax: ↔ increase adverse
reactions related to
GS-3310072: tenofovir disoproxil,
AUC: ↔ including renal disorders.
Cmax: ↔ The safety of tenofovir
Cmin: ↑ 42% disoproxil when used
with
Atazanavir: ledipasvir/sofosbuvir and
AUC: ↔ a pharmacokinetic
Cmax: ↔ enhancer (e.g. ritonavir
Cmin: ↑ 63% or cobicistat) has not
been established.
Ritonavir:
AUC: ↔ The combination should
Cmax: ↔ be used with caution
Cmin: ↑ 45% with frequent renal
monitoring, if other
alternatives are not
Emtricitabine: available (see
AUC: ↔ section 4.4).
Cmax: ↔
Cmin: ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) adefovir dipivoxil (HOS-110478) atazanavir (HOS-086180) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) entecavir (HOS-088124) hepatitis C virus (HOS-108813) didanosine (HOS-085836) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T09:10:00Z · SHA-256 1f0cb3224a43d62885e3f8b0eee2269044880e4d783950c01cb175da2f080514 · Passage 2a1839d03625d3633e5946848228d4de5c1a699fb3a064f076f300e680679815 · Zeichen 6569–13429 im Abschnitt
Wechselwirkungen · Emtricitabine/Tenofovir disoproxil Mylan
Emtricitabine/Tenofovir disoproxil Mylan 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13–14
HOS-134216 · Präparat HOS-097542
13
Medicinal product by Effects on drug Recommendation concerning
therapeutic areas levels co-administration with
Mean percent emtricitabine/tenofovir disoproxil
change in AUC, (emtricitabine 200 mg, tenofovir disoproxil
Cmax, Cmin with 245 mg)
90% confidence
intervals if
available
(mechanism)
Hepatitis C virus (HCV) antiviral agents
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma concentrations of tenofovir
(90 mg/400 mg q.d.) + AUC: ↑ 96% (↑ resulting from co-administration of tenofovir
Atazanavir/Ritonavir 74 to ↑ 121) disoproxil, ledipasvir/sofosbuvir and
(300 mg q.d. /100 mg q.d.) + Cmax: ↑ 68% (↑ 54 atazanavir/ritonavir may increase adverse
Emtricitabine/Tenofovir disoproxil to ↑ 84)
(200 mg/245 mg q.d.)1 reactions related to tenofovir disoproxil,
Cmin: ↑ 118% (↑ including renal disorders. The safety of
91 to ↑ 150) tenofovir disoproxil when used with
ledipasvir/sofosbuvir and a pharmacokinetic
Sofosbuvir: enhancer (e.g. ritonavir or cobicistat) has not
AUC: ↔
Cmax: ↔ been established.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) tenofovir disoproxil (HOS-108843) hepatitis C virus (HOS-108813) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-03T14:25:00Z · SHA-256 dca28001b5f37f5fac24ef504bb45938e413f238844fb60b012f3f9b5a32b40c · Passage 13ce8331ef62ab4a8ac7c9b0519f5abd9c5c25e38a0192fd040164ba19c2d894 · Zeichen 11107–12870 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18–19
HOS-134512 · Präparat HOS-097580
18
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Geometric mean change Recommendations concerning co-
therapeutic areas (%) administration
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Not studied. Concomitant use of When administered concomitantly
bosentan and darunavir co- with darunavir and low dose
administered with low dose ritonavir ritonavir, the patient’s tolerability of
may increase plasma concentrations of bosentan should be monitored.
bosentan.
Bosentan is expected to decrease
plasma concentrations of darunavir
and/or its pharmacoenhancer. (CYP3A
induction)
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
NS3-4A protease inhibitors
Elbasvir/grazoprevir Darunavir with low dose ritonavir may Concomitant use of darunavir with
increase the exposure to grazoprevir. low dose ritonavir and
(CYP3A and OATP1B inhibition). elbasvir/grazoprevir is
contraindicated (see section 4.3).
Glecaprevir/pibrentasvir Based on theoretical considerations It is not recommended to co-
boosted darunavir may increase the administer boosted darunavir with
exposure to glecaprevir and glecaprevir/pibrentasvir.
pibrentasvir.
(P-gp, BCRP and/or OATP1B1/3
inhibition)
HERBAL PRODUCTS
St John's wort Not studied. St John’s wort is expected Darunavir co-administered with low
(Hypericum perforatum) to decrease the plasma concentrations dose ritonavir must not be used
of darunavir and ritonavir. concomitantly with products
(CYP450 induction) containing St John’s wort
(Hypericum perforatum) (see
section 4.3). If a patient is already
taking St John’s wort, stop St
John’s wort and if possible check
viral levels. Darunavir exposure
(and also ritonavir exposure) may
increase on stopping St John’s wort.
The inducing effect may persist for
at least 2 weeks after cessation of
treatment with St John’s wort.
HMG CO-A REDUCTASE INHIBITORS
Lovastatin Not studied. Lovastatin and simvastatin Increased plasma concentrations of
Simvastatin are expected to have markedly lovastatin or simvastatin may cause
increased plasma concentrations when myopathy, including
co-administered with darunavir co- rhabdomyolysis. Concomitant use
administered with low dose ritonavir. of darunavir co-administered with
(CYP3A inhibition) low dose ritonavir with lovastatin
and simvastatin is therefore
contraindicated (see section 4.3).
Atorvastatin atorvastatin AUC ↑ 3-4 fold When administration of atorvastatin
10 mg once daily atorvastatin Cmin ↑ ≈5.5-10 fold and darunavir co- administered with
atorvastatin Cmax ↑ ≈2 fold low dose ritonavir is desired, it is
#
darunavir/ritonavir recommended to start with an
atorvastatin dose of 10 mg once
daily. A gradual dose increase of
atorvastatin may be tailored to the
clinical response.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) protease (HOS-085623) lovastatin (HOS-086157) atorvastatin (HOS-086304) pibrentasvir (HOS-086298) simvastatin (HOS-086158) glecaprevir (HOS-086297) hepatitis C virus (HOS-108813) grazoprevir (HOS-108815) ritonavir (HOS-084521) bosentan (HOS-086291)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 7b1edfe850fde2a2a949b44430e70ed99d603382b1e03aaa3d8a57534a62b67e · Zeichen 48130–53015 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 60–61
HOS-134628 · Präparat HOS-097580
60
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Recommendations concerning co-
therapeutic areas Geometric mean change (%) administration
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Not studied. Concomitant use of When administered concomitantly
bosentan and boosted darunavir with darunavir and low dose
may increase plasma concentrations ritonavir, the patient's tolerability of
of bosentan. bosentan should be monitored.
Bosentan is expected to decrease
plasma concentrations of darunavir Co-administration of darunavir co-
and/or its pharmacoenhancer. administered with cobicistat and
(CYP3A induction) bosentan is not recommended.
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
NS3-4A protease inhibitors
Elbasvir/grazoprevir Boosted darunavir may increase the Concomitant use of boosted
exposure to grazoprevir. darunavir and elbasvir/grazoprevir is
(CYP3A and OATP1B inhibition). contraindicated (see section 4.3).
Glecaprevir/pibrentasvir Based on theoretical considerations It is not recommended to co-
boosted darunavir may increase the administer boosted darunavir with
exposure to glecaprevir and glecaprevir/pibrentasvir.
pibrentasvir.
(P-gp, BCRP and/or OATP1B1/3
inhibition)
HERBAL PRODUCTS
St John's wort Not studied. St John's wort is Boosted darunavir must not be used
(Hypericum perforatum) expected to decrease the plasma concomitantly with products
concentrations of darunavir or its containing St John's wort (Hypericum
pharmacoenhancers. perforatum) (see section 4.3). If a
(CYP450 induction) patient is already taking St John's
wort, stop St John's wort and if
possible check viral levels. Darunavir
exposure (and also ritonavir
exposure) may increase on stopping
St John's wort. The inducing effect
may persist for at least 2 weeks after
cessation of treatment with St John's
wort.
HMG CO-A REDUCTASE INHIBITORS
Lovastatin Not studied. Lovastatin and Increased plasma concentrations of
Simvastatin simvastatin are expected to have lovastatin or simvastatin may cause
markedly increased plasma myopathy, including rhabdomyolysis.
concentrations when co- Concomitant use of boosted
administered with boosted darunavir with lovastatin and
darunavir. simvastatin is therefore
(CYP3A inhibition) contraindicated (see section 4.3).
Atorvastatin atorvastatin AUC ↑ 3-4 fold When administration of atorvastatin
10 mg once daily atorvastatin Cmin ↑ ≈5.5-10 fold and boosted darunavir is desired, it is
atorvastatin Cmax ↑ ≈2 fold recommended to start with an
#
darunavir/ritonavir atorvastatin dose of 10 mg once
daily. A gradual dose increase of
atorvastatin AUC ↑ 290% Ω atorvastatin may be tailored to the
atorvastatin Cmax ↑ 319% Ω clinical response.
atorvastatin Cmin ND Ω
Ω
with darunavir/cobicistat 800/150 mg
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) protease (HOS-085623) lovastatin (HOS-086157) atorvastatin (HOS-086304) pibrentasvir (HOS-086298) cobicistat (HOS-088111) simvastatin (HOS-086158) glecaprevir (HOS-086297) hepatitis C virus (HOS-108813) grazoprevir (HOS-108815) ritonavir (HOS-084521) bosentan (HOS-086291)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage f66edf1b3f3cfbd4637db6965ebe86d3757f4304c50a485b30a8dd4fa4ed1608 · Zeichen 54456–59041 im Abschnitt
Wechselwirkungen · Descovy
Descovy 200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-134942 · Präparat HOS-097638
Co-administration of ketoconazole or
itraconazole, which are potent P-gp
inhibitors, is expected to increase
plasma concentrations of tenofovir
alafenamide.
Fluconazole Interaction not studied with either of Dose Descovy according to the
Isavuconazole the components of Descovy. concomitant antiretroviral (see
section 4.2).
Co-administration of fluconazole or
isavuconazole may increase plasma
concentrations of tenofovir
alafenamide.
Antimycobacterials
Rifabutin Interaction not studied with either of Co-administration of Descovy and
Rifampicin the components of Descovy. rifabutin rifampicin, or rifapentine
Rifapentine is not recommended.
Co-administration of rifampicin,
rifabutin, and rifapentine, all of which
are P-gp inducers, may decrease
tenofovir alafenamide plasma
concentrations, which may result in
loss of therapeutic effect and
development of resistance.
Anti-hepatitis C virus medicinal products
Ledipasvir (90 mg once daily)/ Ledipasvir: No dose adjustment of ledipasvir or
sofosbuvir (400 mg once daily), AUC: ↑ 79% sofosbuvir is required. Dose
emtricitabine (200 mg once Cmax: ↑ 65% Descovy according to the
daily)/ tenofovir alafenamide Cmin: ↑ 93% concomitant antiretroviral (see
(10 mg once daily) 3 section 4.2).
Sofosbuvir:
AUC: ↑ 47%
Cmax: ↑ 29%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) isavuconazole (HOS-085186) sofosbuvir (HOS-108928) ketoconazole (HOS-084513) rifabutin (HOS-086262) ledipasvir (HOS-110493) hepatitis C virus (HOS-108813) itraconazole (HOS-084516) fluconazole (HOS-087945) rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-02-17T15:13:00Z · SHA-256 a11fc916e5e96ef11eeda5a56230a79328fb44e76134aa071c19126c22c2e943 · Passage 5391e3f045a08ca426387b5308c49acd9a067914739bd44d5f63cff33a3b8f7f · Zeichen 3503–5872 im Abschnitt
Wechselwirkungen · Descovy
Descovy 200 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 33
HOS-135011 · Präparat HOS-097638
Co-administration of ketoconazole or
itraconazole, which are potent P-gp
inhibitors, is expected to increase
plasma concentrations of tenofovir
alafenamide.
Fluconazole Interaction not studied with either of Dose Descovy according to the
Isavuconazole the components of Descovy. concomitant antiretroviral (see
section 4.2).
Co-administration of fluconazole or
isavuconazole may increase plasma
concentrations of tenofovir
alafenamide.
Antimycobacterials
Rifabutin Interaction not studied with either of Co-administration of Descovy and
Rifampicin the components of Descovy. rifabutin rifampicin, or rifapentine
Rifapentine is not recommended.
Co-administration of rifampicin,
rifabutin, and rifapentine, all of which
are P-gp inducers, may decrease
tenofovir alafenamide plasma
concentrations, which may result in
loss of therapeutic effect and
development of resistance.
Anti-hepatitis C virus medicinal products
Ledipasvir (90 mg once daily)/ Ledipasvir: No dose adjustment of ledipasvir or
sofosbuvir (400 mg once daily), AUC: ↑ 79% sofosbuvir is required. Dose
emtricitabine (200 mg once Cmax: ↑ 65% Descovy according to the
daily)/ tenofovir alafenamide Cmin: ↑ 93% concomitant antiretroviral (see
(10 mg once daily)3 section 4.2).
Sofosbuvir:
AUC: ↑ 47%
Cmax: ↑ 29%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) isavuconazole (HOS-085186) sofosbuvir (HOS-108928) ketoconazole (HOS-084513) rifabutin (HOS-086262) ledipasvir (HOS-110493) hepatitis C virus (HOS-108813) itraconazole (HOS-084516) fluconazole (HOS-087945) rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-02-17T15:13:00Z · SHA-256 a11fc916e5e96ef11eeda5a56230a79328fb44e76134aa071c19126c22c2e943 · Passage 6c687bbb037e1ba31a8849027e7f435533d859237f7a05c8cfb64e0a18ac4d39 · Zeichen 3504–5873 im Abschnitt
Wechselwirkungen · Tenofovir disoproxil Zentiva
Tenofovir disoproxil Zentiva 245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13–14
HOS-224026 · Präparat HOS-217268
13
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, concerning
(dose in mg) Cmin co-administration with
245 mg tenofovir
disoproxil
Entecavir AUC: ↔ No clinically significant
Cmax: ↔ pharmacokinetic
interactions when
tenofovir disoproxil was
co-administered with
entecavir.
Hepatitis C virus antiviral agents
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma
(90 mg/400 mg q.d.) + AUC: ↑ 96% concentrations of
Atazanavir/Ritonavir Cmax: ↑ 68% tenofovir resulting from
(300 mg q.d./100 mg q.d.) + Cmin: ↑ 118% co-administration of
Emtricitabine/Tenofovir tenofovir disoproxil,
disoproxil ledipasvir/sofosbuvir and
Sofosbuvir:
(200 mg/245 mg q.d.)1 atazanavir/ritonavir may
AUC: ↔
increase adverse
Cmax: ↔
reactions related to
tenofovir disoproxil,
GS-3310072:
including renal disorders.
AUC: ↔
The safety of tenofovir
Cmax: ↔ disoproxil when used
Cmin: ↑ 42% with
ledipasvir/sofosbuvir and
Atazanavir: a pharmacokinetic
AUC: ↔ enhancer (e.g. ritonavir
Cmax: ↔ or cobicistat) has not
Cmin: ↑ 63% been established.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) entecavir (HOS-088124) tenofovir disoproxil (HOS-108843) hepatitis C virus (HOS-108813) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-19T14:26:00Z · SHA-256 d3c0075e2e253b5498aea953ad0fcd47cc3b569eeb05148fdfd0f984d05bbe31 · Passage 6e846166ac48479f8d95ca87e627a48860930df7c8d482452cc34f98de44b389 · Zeichen 9115–11817 im Abschnitt
Wechselwirkungen · Emtricitabine/Tenofovir disoproxil Zentiva
Emtricitabine/Tenofovir disoproxil Zentiva 200 mg / 245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-224296 · Präparat HOS-217300
12
Medicinal product Effects on drug levels Recommendation concerning
by therapeutic areas Mean percent change in AUC, co-administration with
Cmax, Cmin with 90% confidence Emtricitabine/Tenofovir
intervals if available disoproxil Zentiva (emtricitabine
(mechanism) 200 mg, tenofovir disoproxil
245 mg)
ANTI-INFECTIVES
Hepatitis B virus (HBV) antiviral agents
Adefovir dipivoxil /tenofovir Adefovir dipivoxil: Adefovir dipivoxil and
disoproxil AUC: ↓ 11% (↓ 14 to ↓ 7) Emtricitabine/Tenofovir disoproxil
Cmax: ↓ 7% (↓ 13 to ↓ 0) Zentiva should not be administered
Cmin: NC concomitantly (see section 4.4).
Tenofovir:
AUC: ↓ 2% (↓ 5 to ↑ 0)
Cmax: ↓ 1% (↓ 7 to ↑ 6)
Cmin: NC
Hepatitis C virus (HCV) antiviral agents
Ledipasvir/sofosbuvir Ledipasvir: Increased plasma concentrations of
(90 mg/400 mg q.d.) + AUC: ↑96% (↑74 to ↑121) tenofovir resulting from co-
atazanavir/ritonavir Cmax: ↑68% (↑54 to ↑84) administration of tenofovir
Cmin: ↑118% (↑91 to ↑150) disoproxil, ledipasvir/sofosbuvir
(300 mg q.d./100 mg q.d.) +
and atazanavir/ritonavir may
emtricitabine/tenofovir disoproxil Sofosbuvir: increase adverse reactions related to
(200 mg/245 mg q.d.)1 AUC: ↔ tenofovir disoproxil, including renal
Cmax: ↔ disorders. The safety of tenofovir
disoproxil when used with
GS-3310072: ledipasvir/sofosbuvir and a
AUC: ↔ pharmacokinetic enhancer (e.g.
Cmax: ↔ ritonavir or cobicistat) has not been
Cmin: ↑ 42% (↑ 34 to ↑ 49) established.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) adefovir dipivoxil (HOS-110478) atazanavir (HOS-086180) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) tenofovir disoproxil (HOS-108843) hepatitis C virus (HOS-108813) hepatitis B virus (HOS-113725) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-19T01:00:00Z · SHA-256 b5bb27eee5664c354454ec83c92e260583834d02461904425360856edf6a560f · Passage 54a7fb83ed5b791d20573aa35b8583b3b3aadaf7aeb194206ac69c3169c5b602 · Zeichen 10171–12772 im Abschnitt
Wechselwirkungen · Emtricitabine/Tenofovir disoproxil Krka
Emtricitabine/Tenofovir disoproxil Krka 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–14
HOS-136585 · Präparat HOS-097888
11
Lamivudine/Tenofovir disoproxil Lamivudine: Lamivudine and
AUC: ↓ 3% (↓ 8% to ↑ 15) Emtricitabine/Tenofovir disoproxil
Cmax: ↓ 24% (↓ 44 to ↓ 12) Krka should not be administered
Cmin: NC concomitantly (see section 4.4).
Tenofovir:
AUC: ↓ 4% (↓ 15 to ↑ 8)
Cmax: ↑ 102% (↓ 96 to ↑ 108)
Cmin: NC
Efavirenz/Tenofovir disoproxil Efavirenz: No dose adjustment of efavirenz is
AUC: ↓ 4% (↓ 7 to ↓ 1) required.
Cmax: ↓ 4% (↓ 9 to ↑ 2)
Cmin: NC
Tenofovir:
AUC: ↓ 1% (↓ 8 to ↑ 6)
Cmax: ↑ 7% (↓ 6 to ↑ 22)
Cmin: NC
ANTI-INFECTIVES
Hepatitis B virus (HBV) antiviral agents
Adefovir dipivoxil /Tenofovir Adefovir dipivoxil: Adefovir dipivoxil and
disoproxil AUC: ↓ 11% (↓ 14 to ↓ 7) Emtricitabine/Tenofovir disoproxil
Cmax: ↓ 7% (↓ 13 to ↓ 0) Krka should not be administered
Cmin: NC concomitantly (see section 4.4).
Tenofovir:
AUC: ↓ 2% (↓ 5 to ↑ 0)
Cmax: ↓ 1% (↓ 7 to ↑ 6)
Cmin: NC
Hepatitis C virus (HCV) antiviral agents
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma concentrations of
(90 mg/400 mg q.d.) + AUC: ↑ 96% (↑ 74 to ↑ 121) tenofovir resulting from co-
Atazanavir/Ritonavir Cmax: ↑ 68% (↑ 54 to ↑ 84) administration of tenofovir disoproxil,
(300 mg q.d./100 mg q.d.) + Cmin: ↑ 118% (↑ 91 to ↑ 150) ledipasvir/sofosbuvir and
Emtricitabine/Tenofovir disoproxil Sofosbuvir: atazanavir/ritonavir may increase
(200 mg/245 mg q.d.)1 AUC: ↔ adverse reactions related to tenofovir
Cmax: ↔ disoproxil, including renal disorders.
GS-3310072: The safety of tenofovir disoproxil when
AUC: ↔ used with ledipasvir/sofosbuvir and a
Cmax: ↔ pharmacokinetic enhancer (e.g.
Cmin: ↑ 42% (↑ 34 to ↑ 49) ritonavir or cobicistat) has not been
Atazanavir: established.
AUC: ↔ The combination should be used with
Cmax: ↔ caution with frequent renal monitoring,
Cmin: ↑ 63% (↑ 45 to ↑ 84) if other alternatives are not available
Ritonavir: (see section 4.4).
AUC: ↔
Cmax: ↔
Cmin: ↑ 45% (↑ 27 to ↑ 64)
Emtricitabine:
AUC: ↔
Cmax: ↔
Cmin: ↔
Tenofovir:
AUC: ↔
Cmax: ↑ 47% (↑ 37 to ↑ 58)
Cmin: ↑ 47% (↑ 38 to ↑ 57)
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma concentrations of
(90 mg/400 mg q.d.) + AUC: ↔ tenofovir resulting from co-
Darunavir/Ritonavir Cmax: ↔ administration of tenofovir disoproxil,
(800 mg q.d./100 mg q.d.) + Cmin: ↔ ledipasvir/sofosbuvir and
Emtricitabine/Tenofovir disoproxil Sofosbuvir: darunavir/ritonavir may increase
(200 mg/245 mg q.d.)1 AUC: ↓ 27% (↓ 35 to ↓ 18) adverse reactions related to tenofovir
12
Cmax: ↓ 37% (↓ 48 to ↓ 25) disoproxil, including renal disorders.
GS-3310072: The safety of tenofovir disoproxil when
AUC: ↔ used with ledipasvir/sofosbuvir and a
Cmax: ↔ pharmacokinetic enhancer (e.g.
Cmin: ↔ ritonavir or cobicistat) has not been
Darunavir: established.
AUC: ↔ The combination should be used with
Cmax: ↔ caution with frequent renal monitoring,
Cmin: ↔ if other alternatives are not available
Ritonavir: (see section 4.4).
AUC: ↔
Cmax: ↔
Cmin: ↑ 48% (↑ 34 to ↑ 63)
Emtricitabine:
AUC: ↔
Cmax: ↔
Cmin: ↔
Tenofovir:
AUC: ↑ 50% (↑ 42 to ↑ 59)
Cmax: ↑ 64% (↑ 54 to ↑ 74)
Cmin: ↑ 59% (↑ 49 to ↑ 70)
Ledipasvir/Sofosbuvir Ledipasvir: No dose adjustment is recommended.
(90 mg/400 mg q.d.) + AUC: ↓ 34% (↓ 41 to ↓ 25) The increased exposure of tenofovir
Efavirenz/Emtricitabine/Tenofovir Cmax: ↓ 34% (↓ 41 to ↑ 25) could potentiate adverse reactions
disoproxil Cmin: ↓ 34% (↓ 43 to ↑ 24) associated with tenofovir disoproxil,
(600 mg/200 mg/245 mg q.d.) Sofosbuvir: including renal disorders. Renal
AUC: ↔ function should be closely monitored
Cmax: ↔ (see section 4.4).
GS-3310072:
AUC: ↔
Cmax: ↔
Cmin: ↔
Efavirenz:
AUC: ↔
Cmax: ↔
Cmin: ↔
Emtricitabine:
AUC: ↔
Cmax: ↔
Cmin: ↔
Tenofovir:
AUC: ↑ 98% (↑ 77 to ↑ 123)
Cmax: ↑ 79% (↑ 56 to ↑ 104)
Cmin: ↑ 163% (↑ 137 to ↑ 197)
Ledipasvir/Sofosbuvir Ledipasvir: No dose adjustment is recommended.
(90 mg/400 mg q.d.) + AUC: ↔ The increased exposure of tenofovir
Emtricitabine/Rilpivirine/ Tenofovir Cmax: ↔ could potentiate adverse reactions
disoproxil Cmin: ↔ associated with tenofovir disoproxil,
(200 mg/25 mg/245 mg q.d.) Sofosbuvir: including renal disorders. Renal
AUC: ↔ function should be closely monitored
Cmax: ↔ (see section 4.4).
GS-3310072:
AUC: ↔
Cmax: ↔
Cmin: ↔
Emtricitabine:
AUC: ↔
Cmax: ↔
Cmin: ↔
Rilpivirine:
AUC: ↔
Cmax: ↔
13
Cmin: ↔
Tenofovir:
AUC: ↑ 40% (↑ 31 to ↑ 50)
Cmax: ↔
Cmin: ↑ 91% (↑ 74 to ↑ 110)
Ledipasvir/Sofosbuvir Sofosbuvir: No dose adjustment is required. The
(90 mg/400 mg q.d.) + Dolutegravir AUC: ↔ increased exposure of tenofovir could
(50 mg q.d.) + Cmax: ↔ potentiate adverse reactions associated
Emtricitabine/Tenofovir disoproxil with tenofovir disoproxil, including
(200 mg/245 mg q.d.) GS-3310072 renal disorders. Renal function should
AUC: ↔ be closely monitored (see section 4.4).
Cmax: ↔
Cmin: ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) adefovir dipivoxil (HOS-110478) atazanavir (HOS-086180) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) dolutegravir (HOS-089992) hepatitis C virus (HOS-108813) lamivudine (HOS-085829) rilpivirine (HOS-088090) darunavir (HOS-086181) hepatitis B virus (HOS-113725) efavirenz (HOS-087947) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-31T12:47:00Z · SHA-256 bff22a935481266901d4c92f1163f09cb1d50edd80ede33ac1750318fed62b8d · Passage ef1a7c3e42b38e99972a859eaae7af1573783b27f7b434b743e8cd7a9897fd81 · Zeichen 7896–17795 im Abschnitt
Wechselwirkungen · Darunavir Krka
Darunavir Krka 400 mg film-coated tablets Darunavir Krka 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18–19
HOS-225728 · Präparat HOS-217490
18
co-administered with boosted darunavir,
resulting in reduced serum cortisol
concentrations.
Dexamethasone (systemic) Not studied. Dexamethasone may decrease Systemic dexamethasone should be
plasma concentrations of darunavir. used with caution when combined
(CYP3A induction) with boosted darunavir.
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Not studied. Concomitant use of bosentan When administered concomitantly
and boosted darunavir may increase with darunavir and low dose
plasma concentrations of bosentan. ritonavir, the patient's tolerability of
Bosentan is expected to decrease plasma bosentan should be monitored.
concentrations of darunavir and/or its Co administration of darunavir co-
pharmacoenhancer. administered with cobicistat and
(CYP3A induction) bosentan is not recommended.
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
NS3-4A protease inhibitors
Elbasvir/grazoprevir Boosted darunavir may increase the Concomitant use of boosted
exposure to grazoprevir. darunavir and elbasvir/grazoprevir is
(CYP3A and OATP1B inhibition) contraindicated (see section 4.3).
Glecaprevir/pibrentasvir Based on theoretical considerations It is not recommended to
boosted darunavir may increase the co-administer boosted darunavir with
exposure to glecaprevir and pibrentasvir. glecaprevir/pibrentasvir.
(P-gp, BCRP and/or OATP1B1/3
inhibition)
HERBAL PRODUCTS
St John's wort (Hypericum Not studied. St John's wort is expected to Boosted darunavir must not be used
perforatum) decrease the plasma concentrations of concomitantly with products
darunavir or its pharmacoenhancers. containing St John's wort
(CYP450 induction) (Hypericum perforatum) (see section
4.3). If a patient is already taking St
John's wort, stop St John's wort and
if possible check viral levels.
Darunavir exposure (and also
ritonavir exposure) may increase on
stopping St John's wort. The
inducing effect may persist for at
least 2 weeks after cessation of
treatment with St John's wort.
HMG CO-A REDUCTASE INHIBITORS
Lovastatin Not studied. Lovastatin and simvastatin are Increased plasma concentrations of
Simvastatin expected to have markedly increased lovastatin or simvastatin may cause
plasma concentrations when co- myopathy, including
administered with boosted darunavir. rhabdomyolysis. Concomitant use of
(CYP3A inhibition) boosted darunavir with lovastatin and
simvastatin is therefore
contraindicated (see section 4.3).
Atorvastatin atorvastatin AUC ↑ 3-4 fold When administration of atorvastatin
10 mg once daily atorvastatin Cmin ↑ ≈5.5-10 fold and boosted darunavir is desired, it is
atorvastatin Cmax ↑ ≈2 fold recommended to start with an
#
darunavir/ritonavir atorvastatin dose of 10 mg once
daily. A gradual dose increase of
atorvastatin may be tailored to the
atorvastatin AUC ↑ 290% Ω clinical response.
atorvastatin Cmax ↑ 319% Ω
atorvastatin Cmin ND Ω
Ω
with darunavir/cobicistat 800/150 mg
Pravastatin pravastatin AUC ↑ 81%¶ When administration of pravastatin
40 mg single dose pravastatin Cmin ND and boosted darunavir is required, it
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) protease (HOS-085623) lovastatin (HOS-086157) atorvastatin (HOS-086304) pibrentasvir (HOS-086298) cobicistat (HOS-088111) simvastatin (HOS-086158) glecaprevir (HOS-086297) hepatitis C virus (HOS-108813) dexamethasone (HOS-084535) grazoprevir (HOS-108815) ritonavir (HOS-084521) bosentan (HOS-086291) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-28T02:00:00Z · SHA-256 42a250050090ba77cfec6bb0ff0fc9dbbb4e1a422df7d45e8efc6fc459616a05 · Passage 4ac84be90015685ee8df12207b90723e6fd5eedb2272e3eb59e7efd7ce8a26f7 · Zeichen 51082–56416 im Abschnitt
Wechselwirkungen · Darunavir Krka
Darunavir Krka 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53–54
HOS-225812 · Präparat HOS-217490
53
Carvedilol Not studied. Darunavir is expected to Clinical monitoring is recommended
Metoprolol increase these β-blocker plasma when co-administering darunavir
Timolol concentrations. with β-blockers. A lower dose of the
(CYP2D6 inhibition) β-blocker should be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. Darunavir co-administered Clinical monitoring of therapeutic
Diltiazem with low dose ritonavir can be expected to and adverse reactions is
Felodipine increase the plasma concentrations of recommended when these medicines
Nicardipine calcium channel blockers. are concomitantly administered with
Nifedipine (CYP3A and/or CYP2D6 inhibition) darunavir with low dose ritonavir.
Verapamil
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of darunavir with
metabolised by CYP3A ritonavir 100 mg capsules twice daily were low dose ritonavir and
(including betamethasone, co-administered with 50 μg intranasal corticosteroids (all routes of
budesonide, fluticasone, fluticasone propionate (4 times daily) for administration) that are metabolised
mometasone, prednisone, 7 days in healthy subjects, fluticasone by CYP3A may increase the risk of
triamcinolone) propionate plasma concentrations development of systemic
increased significantly, whereas the corticosteroid effects, including
intrinsic cortisol levels decreased by Cushing's syndrome and adrenal
approximately 86% (90% CI 82-89%). suppression.
Greater effects may be expected when
fluticasone is inhaled. Systemic Co-administration with CYP3A-
corticosteroid effects including Cushing's metabolised corticosteroids is not
syndrome and adrenal suppression have recommended unless the potential
been reported in patients receiving benefit to the patient outweighs the
ritonavir and inhaled or intranasally risk, in which case patients should be
administered fluticasone. The effects of monitored for systemic corticosteroid
high fluticasone systemic exposure on effects.
ritonavir plasma levels are unknown.
Other corticosteroids: interaction not Alternative corticosteroids which are
studied. Plasma concentrations of these less dependent on CYP3A
medicinal products may be increased when metabolism e.g. beclomethasone
co-administered with darunavir with low should be considered, particularly for
dose ritonavir, resulting in reduced serum long term use.
cortisol concentrations.
Dexamethasone (systemic) Not studied. Dexamethasone may decrease Systemic dexamethasone should be
plasma concentrations of darunavir. used with caution when combined
(CYP3A induction) with darunavir co-administered with
low dose ritonavir.
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Not studied. Concomitant use of bosentan When administered concomitantly
and darunavir co-administered with low with darunavir A and low dose
dose ritonavir may increase plasma ritonavir, the patient's tolerability of
concentrations of bosentan. bosentan should be monitored.
Bosentan is expected to decrease plasma
concentrations of darunavir and/or its
pharmacoenhancer.
(CYP3A induction)
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
NS3-4A protease inhibitors
Elbasvir/grazoprevir Darunavir with low dose ritonavir may Concomitant use of darunavir with
increase the exposure to grazoprevir. low dose ritonavir and
(CYP3A and OATP1B inhibition) elbasvir/grazoprevir is
contraindicated (see section 4.3).
Glecaprevir/pibrentasvir Based on theoretical considerations It is not recommended to
boosted darunavir may increase the co-administer boosted darunavir with
exposure to glecaprevir and pibrentasvir. glecaprevir/pibrentasvir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) elbasvir (HOS-108814) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) protease (HOS-085623) pibrentasvir (HOS-086298) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) amlodipine (HOS-086287) glecaprevir (HOS-086297) calcium (HOS-085615) hepatitis C virus (HOS-108813) betamethasone (HOS-090066) dexamethasone (HOS-084535) grazoprevir (HOS-108815) budesonide (HOS-086332) mometasone (HOS-114048) propionate (HOS-108915) ritonavir (HOS-084521) beclomethasone (HOS-086334) bosentan (HOS-086291) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-28T02:00:00Z · SHA-256 42a250050090ba77cfec6bb0ff0fc9dbbb4e1a422df7d45e8efc6fc459616a05 · Passage 6feb23a71b47d8a87c3462532727ed6909fdd43acbc01669dbaec29dd46f5994 · Zeichen 40889–45960 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14–15
HOS-138493 · Präparat HOS-098200
14
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Based on theoretical considerations Co-administration of Symtuza
bosentan is expected to decrease and bosentan is not
darunavir and/or cobicistat plasma recommended.
concentrations.
(CYP3A induction)
Symtuza is expected to increase
bosentan plasma concentrations.
(CYP3A inhibition)
ERGOT DERIVATIVES
e.g. Based on theoretical considerations Co-administration of Symtuza
Dihydroergotamine DRV/COBI may increase ergot and ergot derivatives is
Ergometrine derivative exposure. contraindicated (see section 4.3).
Ergotamine
Methylergonovine
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
NS3-4A inhibitors
Elbasvir/grazoprevir Based on theoretical considerations Concomitant use of Symtuza with
Symtuza may increase the elbasvir/grazoprevir is
exposure to grazoprevir. contraindicated (see section 4.3).
(OATP1B and CYP3A inhibition)
Glecaprevir/pibrentasvir Based on theoretical considerations It is not recommended to
DRV/COBI may increase the co-administer Symtuza with
exposure to glecaprevir and glecaprevir/pibrentasvir.
pibrentasvir.
(P-gp, BCRP and/or OATP1B1/3
inhibition)
Daclatasvir Based on theoretical Symtuza and sofosbuvir,
Ledipasvir considerations, no clinically sofosbuvir/ledipasvir, or
Sofosbuvir relevant interaction is expected. daclatasvir can be used
concomitantly without dose
adjustment
Herbal products
St. John’s Wort (Hypericum
Based on theoretical consideration, The concomitant use of Symtuza
perforatum) St. John’s Wort may substantially with these medicinal products is
decrease DRV/COBI (CYP3A4 contraindicated (see section 4.3).
induction) and TAF exposures.
(P-gp induction)
HMG CO-A REDUCTASE INHIBITORS
Atorvastatin Atorvastatin (10 mg once daily): Concomitant use of a HMG CoA
Fluvastatin atorvastatin AUC ↑ 290% reductase inhibitor and Symtuza
Pitavastatin atorvastatin Cmax ↑ 319% may increase plasma
Pravastatin atorvastatin Cmin ND concentrations of the lipid
Rosuvastatin lowering agent, which may lead
Rosuvastatin (10 mg once daily): to adverse reactions such as
rosuvastatin AUC ↑ 93% myopathy.
rosuvastatin Cmax ↑ 277% When administration of
rosuvastatin Cmin ND HMG CoA reductase inhibitors
and Symtuza is desired, it is
Based on theoretical considerations recommended to start with the
DRV/COBI is expected to increase lowest dose and titrate up to the
the plasma concentrations of desired clinical effect while
fluvastatin, pitavastatin, monitoring for safety.
pravastatin, lovastatin and
Lovastatin simvastatin. Concomitant use of Symtuza with
Simvastatin (CYP3A inhibition and/or lovastatin and simvastatin is
transport) contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) methylergonovine (HOS-086155) daclatasvir (HOS-119742) sofosbuvir (HOS-108928) lovastatin (HOS-086157) atorvastatin (HOS-086304) pibrentasvir (HOS-086298) ledipasvir (HOS-110493) simvastatin (HOS-086158) rosuvastatin (HOS-086307) glecaprevir (HOS-086297) fluvastatin (HOS-086305) hepatitis C virus (HOS-108813) lead (HOS-085592) grazoprevir (HOS-108815) ergotamine (HOS-086154) bosentan (HOS-086291) dihydroergotamine (HOS-086152) pravastatin (HOS-086306) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 7dedc11142e46d7502bc7e251f11ffb3c178eac67ce8ce16fb9ccc902e5f3904 · Zeichen 28527–32949 im Abschnitt
Wechselwirkungen · Biktarvy
Biktarvy 30 mg/120 mg/15 mg film-coated tablets Biktarvy 50 mg/200 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-139284 · Präparat HOS-098314
(Inhibition of CYP3A, UGT1A1,
and P-gp/BCRP)
Atazanavir (400 mg once daily), Bictegravir:
Bictegravir1 AUC: ↑ 315%
Cmax: ↔
(Inhibition of CYP3A and
UGT1A1)
Hepatitis C virus antiviral agents
Ledipasvir/Sofosbuvir Bictegravir: No dose adjustment is required
(90 mg/400 mg once daily), AUC: ↔ upon co-administration.
Bictegravir/Emtricitabine/ Cmin: ↔
Tenofovir alafenamide2 Cmax: ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) hepatitis C virus (HOS-108813)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T17:05:00Z · SHA-256 8ec4738243d92aa421e74b71a9bad453e15421c1f952d3be4e88479f189e0fe4 · Passage 7d9f2af90414c858180ac24c73e8fba37e12508fdf01fb61b79972a1f9a92b8b · Zeichen 6775–7326 im Abschnitt
Wechselwirkungen · Emtricitabine/Tenofovir disoproxil Krka d.d.
Emtricitabine/Tenofovir disoproxil Krka d.d. 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–13
HOS-289817 · Präparat HOS-287252
10
AUC: ↓ 4% (↓ 15 to ↑ 8)
Cmax: ↑ 102% (↓ 96 to ↑ 108)
Cmin: NC
Efavirenz/Tenofovir disoproxil Efavirenz: No dose adjustment of efavirenz is
AUC: ↓ 4% (↓ 7 to ↓ 1) required.
Cmax: ↓ 4% (↓ 9 to ↑ 2)
Cmin: NC
Tenofovir:
AUC: ↓ 1% (↓ 8 to ↑ 6)
Cmax: ↑ 7% (↓ 6 to ↑ 22)
Cmin: NC
ANTI-INFECTIVES
Hepatitis B virus (HBV) antiviral agents
Adefovir dipivoxil /Tenofovir Adefovir dipivoxil: Adefovir dipivoxil and
disoproxil AUC: ↓ 11% (↓ 14 to ↓ 7) Emtricitabine/Tenofovir disoproxil
Cmax: ↓ 7% (↓ 13 to ↓ 0) Krka d.d. should not be administered
Cmin: NC concomitantly (see section 4.4).
Tenofovir:
AUC: ↓ 2% (↓ 5 to ↑ 0)
Cmax: ↓ 1% (↓ 7 to ↑ 6)
Cmin: NC
Hepatitis C virus (HCV) antiviral agents
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma concentrations of
(90 mg/400 mg q.d.) + AUC: ↑ 96% (↑ 74 to ↑ 121) tenofovir resulting from co-
Atazanavir/Ritonavir Cmax: ↑ 68% (↑ 54 to ↑ 84) administration of tenofovir disoproxil,
(300 mg q.d./100 mg q.d.) + Cmin: ↑ 118% (↑ 91 to ↑ 150) ledipasvir/sofosbuvir and
Emtricitabine/Tenofovir disoproxil Sofosbuvir: atazanavir/ritonavir may increase
(200 mg/245 mg q.d.)1 AUC: ↔ adverse reactions related to tenofovir
Cmax: ↔ disoproxil, including renal disorders.
GS-3310072: The safety of tenofovir disoproxil when
AUC: ↔ used with ledipasvir/sofosbuvir and a
Cmax: ↔ pharmacokinetic enhancer (e.g.
Cmin: ↑ 42% (↑ 34 to ↑ 49) ritonavir or cobicistat) has not been
Atazanavir: established.
AUC: ↔ The combination should be used with
Cmax: ↔ caution with frequent renal monitoring,
Cmin: ↑ 63% (↑ 45 to ↑ 84) if other alternatives are not available
Ritonavir: (see section 4.4).
AUC: ↔
Cmax: ↔
Cmin: ↑ 45% (↑ 27 to ↑ 64)
Emtricitabine:
AUC: ↔
Cmax: ↔
Cmin: ↔
Tenofovir:
AUC: ↔
Cmax: ↑ 47% (↑ 37 to ↑ 58)
Cmin: ↑ 47% (↑ 38 to ↑ 57)
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma concentrations of
(90 mg/400 mg q.d.) + AUC: ↔ tenofovir resulting from co-
Darunavir/Ritonavir Cmax: ↔ administration of tenofovir disoproxil,
(800 mg q.d./100 mg q.d.) + Cmin: ↔ ledipasvir/sofosbuvir and
Emtricitabine/Tenofovir disoproxil Sofosbuvir: darunavir/ritonavir may increase
(200 mg/245 mg q.d.)1 AUC: ↓ 27% (↓ 35 to ↓ 18) adverse reactions related to tenofovir
Cmax: ↓ 37% (↓ 48 to ↓ 25) disoproxil, including renal disorders.
GS-3310072: The safety of tenofovir disoproxil when
11
AUC: ↔ used with ledipasvir/sofosbuvir and a
Cmax: ↔ pharmacokinetic enhancer (e.g.
Cmin: ↔ ritonavir or cobicistat) has not been
Darunavir: established.
AUC: ↔ The combination should be used with
Cmax: ↔ caution with frequent renal monitoring,
Cmin: ↔ if other alternatives are not available
Ritonavir: (see section 4.4).
AUC: ↔
Cmax: ↔
Cmin: ↑ 48% (↑ 34 to ↑ 63)
Emtricitabine:
AUC: ↔
Cmax: ↔
Cmin: ↔
Tenofovir:
AUC: ↑ 50% (↑ 42 to ↑ 59)
Cmax: ↑ 64% (↑ 54 to ↑ 74)
Cmin: ↑ 59% (↑ 49 to ↑ 70)
Ledipasvir/Sofosbuvir Ledipasvir: No dose adjustment is recommended.
(90 mg/400 mg q.d.) + AUC: ↓ 34% (↓ 41 to ↓ 25) The increased exposure of tenofovir
Efavirenz/Emtricitabine/Tenofovir Cmax: ↓ 34% (↓ 41 to ↑ 25) could potentiate adverse reactions
disoproxil Cmin: ↓ 34% (↓ 43 to ↑ 24) associated with tenofovir disoproxil,
(600 mg/200 mg/245 mg q.d.) Sofosbuvir: including renal disorders. Renal
AUC: ↔ function should be closely monitored
Cmax: ↔ (see section 4.4).
GS-3310072:
AUC: ↔
Cmax: ↔
Cmin: ↔
Efavirenz:
AUC: ↔
Cmax: ↔
Cmin: ↔
Emtricitabine:
AUC: ↔
Cmax: ↔
Cmin: ↔
Tenofovir:
AUC: ↑ 98% (↑ 77 to ↑ 123)
Cmax: ↑ 79% (↑ 56 to ↑ 104)
Cmin: ↑ 163% (↑ 137 to ↑ 197)
Ledipasvir/Sofosbuvir Ledipasvir: No dose adjustment is recommended.
(90 mg/400 mg q.d.) + AUC: ↔ The increased exposure of tenofovir
Emtricitabine/Rilpivirine/ Tenofovir Cmax: ↔ could potentiate adverse reactions
disoproxil Cmin: ↔ associated with tenofovir disoproxil,
(200 mg/25 mg/245 mg q.d.) Sofosbuvir: including renal disorders. Renal
AUC: ↔ function should be closely monitored
Cmax: ↔ (see section 4.4).
GS-3310072:
AUC: ↔
Cmax: ↔
Cmin: ↔
Emtricitabine:
AUC: ↔
Cmax: ↔
Cmin: ↔
Rilpivirine:
AUC: ↔
12
Cmax: ↔
Cmin: ↔
Tenofovir:
AUC: ↑ 40% (↑ 31 to ↑ 50)
Cmax: ↔
Cmin: ↑ 91% (↑ 74 to ↑ 110)
Ledipasvir/Sofosbuvir Sofosbuvir: No dose adjustment is required. The
(90 mg/400 mg q.d.) + Dolutegravir AUC: ↔ increased exposure of tenofovir could
(50 mg q.d.) + Cmax: ↔ potentiate adverse reactions associated
Emtricitabine/Tenofovir disoproxil with tenofovir disoproxil, including
(200 mg/245 mg q.d.) GS-3310072 renal disorders. Renal function should
AUC: ↔ be closely monitored (see section 4.4).
Cmax: ↔
Cmin: ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) adefovir dipivoxil (HOS-110478) atazanavir (HOS-086180) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) dolutegravir (HOS-089992) hepatitis C virus (HOS-108813) rilpivirine (HOS-088090) darunavir (HOS-086181) hepatitis B virus (HOS-113725) efavirenz (HOS-087947) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-05T15:00:00Z · SHA-256 fff03d74f4fd2f4f4bee32cf8fd60af5ae172b13372b4be32156dfe9a6fcd439 · Passage 6b45892c485684fcd71b6c845e07118614044489a6dbce620c3fedb6f72996a6 · Zeichen 8300–17751 im Abschnitt
Wechselwirkungen · Rukobia
Rukobia 600 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-291979 · Präparat HOS-287582
8
Hepatitis C virus Direct- Grazoprevir This interaction has not been studied.
Acting Antivirals (HCV (inhibition of OATP1B1/3) Temsavir may increase grazoprevir
DAAs): plasma concentrations to a clinically
Elbasvir/Grazoprevir relevant extent caused by
OATP1B1/3 inhibition by temsavir.
Co-administration of fostemsavir with
elbasvir/grazoprevir is not
recommended as increased
grazoprevir concentrations may
increase the risk of ALT elevations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) hepatitis C virus (HOS-108813) temsavir (HOS-291947) grazoprevir (HOS-108815)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-31T17:30:00Z · SHA-256 9ebbfd7323457434a379de509faa041f46600b88f5de77f6f93e77e34487c382 · Passage 24e4649ec2ad5d54f60347f97a31311059787006df5052b94e08445474321f9f · Zeichen 14424–15406 im Abschnitt
Wechselwirkungen · Ryeqo
Ryeqo 40 mg/1 mg/0.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-293731 · Präparat HOS-287948
8
the exposure of relugolix, including certain anti-infective medicinal products (e.g. erythromycin,
clarithromycin, gentamicin, tetracycline), anti-fungal medicinal products (ketoconazole, itraconazole),
antihypertensive medicinal products (e.g. carvedilol, verapamil), antiarrhythmic medicinal products
(e.g. amiodarone, dronedarone, propafenone, quinidine), antianginal medicinal products (e.g.
ranolazine), cyclosporine, human immunodeficiency virus (HIV) or hepatitis C virus (HCV) protease
inhibitors (e.g. ritonavir, telaprevir). If concomitant use with once or twice daily oral P-gp inhibitors is
unavoidable (e.g. azithromycin), take Ryeqo first, and separate dosing with the P-gp inhibitor by at
least 6 hours and monitor patients more frequently for adverse reactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) dronedarone (HOS-086144) protease (HOS-085623) tetracycline (HOS-115153) ketoconazole (HOS-084513) carvedilol (HOS-115322) quinidine (HOS-085593) azithromycin (HOS-088112) hepatitis C virus (HOS-108813) telaprevir (HOS-090618) itraconazole (HOS-084516) clarithromycin (HOS-084517) erythromycin (HOS-084514) ritonavir (HOS-084521) amiodarone (HOS-085596) gentamicin (HOS-091173) ranolazine (HOS-086141) cyclosporine (HOS-084512) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T13:42:00Z · SHA-256 47ea1d2eb5f5688c8be1ae039431bea9dad8dcc4fd014919ff831ceed18491bd · Passage 681cf8359c4661e9223498496dad36a19c12274f353840a7f3c72608b450945a · Zeichen 713–1493 im Abschnitt
Wechselwirkungen · Orgovyx
Orgovyx 120 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-146580 · Präparat HOS-099534
Abbreviations: QD: once a day, BID: twice a day, QID: four times a day, HIV: human
immunodeficiency virus, HCV: hepatitis C virus.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): hepatitis C virus (HOS-108813)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T16:34:00Z · SHA-256 83d5275c068e4da33497bf48ce37dfa4eca293d7cd335add5247289a5323daa8 · Passage db1d085fe8d4d108197c3a9ee99197acef82ce47629fde43e16e2d1e22c3cb8a · Zeichen 15856–15986 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.